<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cyclophosphamide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00531</strong>&#160; (APRD00408)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00531/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00531/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00531.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00531.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00531.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00531.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00531.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00531">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+-)-Cyclophosphamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(RS)-Cyclophosphamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ciclofosfamida</td><td>Spanish</td><td>INN</td></tr><tr><td>Ciclofosfamide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Cyclophosphamid</td><td>German</td><td>INN</td></tr><tr><td>Cyclophosphamide</td><td>French</td><td>INN</td></tr><tr><td>Cyclophosphamide anhydrous</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cyclophosphamidum</td><td>Latin</td><td>INN</td></tr><tr><td>Cytophosphane</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ledoxina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cytoxan</td><td>Bristol-Myers Squibb</td></tr><tr><td>Endoxan</td><td>Actavis</td></tr><tr><td>Neosar</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Procytox</td><td>Baxter</td></tr><tr><td>Revimmune</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sendoxan</td><td>Baxter</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antirheumatic-agents">Antirheumatic Agents</a></li>
<li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/antineoplastic-agents-alkylating">Antineoplastic Agents, Alkylating</a></li>
<li><a href="/mesh/mutagens">Mutagens</a></li>
<li><a href="/mesh/myeloablative-agonists">Myeloablative Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>50-18-0</td></tr><tr><th>Weight</th><td>Average: 261.086<br>Monoisotopic: 260.02481966</td></tr><tr><th>Chemical Formula</th><td>C<sub>7</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>P</td></tr><tr><th>InChI Key</th><td>CMSMOCZEIVJLDB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[bis(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">ClCCN(CCCl)P1(=O)NCCCO1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00531.gif?1265922773">show</a>(9.91 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Tertiary Amines</td></tr><tr><th>Direct parent</th><td>Nitrogen Mustard Compounds</td></tr><tr><th>Alternative parents</th><td>Phosphorodiamides; Oxazaphosphinanes; Organophosphate Esters; Polyamines; Organochlorides; Alkyl Chlorides</td></tr><tr><th>Substituents</th><td>phosphorodiamide; phosphoric acid ester; oxazaphosphinane; polyamine; organochloride; organohalogen; alkyl halide; alkyl chloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a phosphorus atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. </td></tr><tr><th>Pharmacodynamics</th><td>Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.</td></tr><tr><th>Mechanism of action</th><td>Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.</td></tr><tr><th>Absorption</th><td>After oral administration, peak concentrations occur at one hour. </td></tr><tr><th>Volume of distribution</th><td><p>30-50 L</p></td></tr><tr><th>Protein binding</th><td>20% of cyclophosphamide is protein bound with no dose dependent changes. Some metabolites are protein bound to an extent greater than 60%. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Cyclophosphamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00019">4-Hydroxycyclophosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/19">Details</a></td></tr><tr><td>Cyclophosphamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00020">Dechloroethyl cyclophosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/20">Details</a></td></tr><tr><td>Cyclophosphamide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00023">Chloroacetaldehyde</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1133">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00019">4-Hydroxycyclophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET01076">4-Ketocyclophosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1141">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00019">4-Hydroxycyclophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1157">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01088">Carboxyphosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1158">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000227" target="_blank">Alcohol dehydrogenase 1A</a></li>
<li><a href="/biodb/bio_entities/BE0004352" target="_blank">Alcohol dehydrogenase [NADP(+)]</a></li></ul></td><td><a href="/metabolites/DBMET01123">Alcophosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1228">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000718" target="_blank">Aldehyde dehydrogenase, dimeric NADP-preferring</a></li>
<li><a href="/biodb/bio_entities/BE0000583" target="_blank">Aldehyde dehydrogenase family 1 member A3</a></li>
<li><a href="/biodb/bio_entities/BE0000446" target="_blank">Aldehyde dehydrogenase family 3 member B1</a></li>
<li><a href="/biodb/bio_entities/BE0000193" target="_blank">Aldehyde dehydrogenase family 3 member B2</a></li></ul></td><td><a href="/metabolites/DBMET01088">Carboxyphosphamide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1231">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01088">Carboxyphosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01125">Nornitrogen mustard</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1232">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01126">Acrolein</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1233">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01126">Acrolein</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000718" target="_blank">Aldehyde dehydrogenase, dimeric NADP-preferring</a></li>
<li><a href="/biodb/bio_entities/BE0000554" target="_blank">Retinal dehydrogenase 1</a></li></ul></td><td><a href="/metabolites/DBMET01146">Acrylic Acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1275">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00658">Aldophosphamide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01147">Phosphoramide Mustard</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1276">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01147">Phosphoramide Mustard</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01148">Phosphoramide Aziridinium</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1277">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Cyclophosphamide is eliminated primarily in the form of metabolites. 10-20% is excreted unchanged in the urine and 4% is excreted in the bile following IV administration. </td></tr><tr><th>Half life</th><td>3-12 hours</td></tr><tr><th>Clearance</th><td><p>Total body clearance = 63 &#177; 7.6 L/kg.</p></td></tr><tr><th>Toxicity</th><td>Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.
</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Cyclophosphamide Action Pathway</td><td>Drug action</td></tr><tr><td>Cyclophosphamide Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00604?highlight%5Bcompounds%5D%5B%5D=DB00531&amp;highlight%5Bproteins%5D%5B%5D=DB00531">SMP00604</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 3A4<br>Gene symbol: CYP3A4<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08684" target="_blank">P08684 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2740574" target="_blank">rs2740574 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP3A4 *1B</td><td>G Allelle</td><td>Decreased&#160;activation of cyclophosphamide most likely contributing to worse disease free survival&#160;in adjuvant chemotherapy for node-positive breast cancer</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/20459744" target="_blank" title='# Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A: Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010;12(3):R26. doi: 10.1186/bcr2570. Epub 2010 May 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20459744'>20459744 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cytochrome P450 2B6<br>Gene symbol: CYP2B6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P20813" target="_blank">P20813 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>CYP2B6*1G</td><td>C Allelle</td><td>Decreased activation of cyclophosphamide contributing to less adverse reactions (leukocytopenia)</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17502835" target="_blank" title='# Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H: Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007 Jun;17(6):431-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17502835'>17502835 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9722</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.971</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5451</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.71</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.779</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9797</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8125</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7856</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.5884</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5461</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9737</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9146
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8727
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9511
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.3855 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.8419
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Baxter healthcare corp</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Teva parenteral medicines inc</li>
<li>Roxane laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.meda.se">Meda AB</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>200 mg, 500 mg, 1 g, 2 g</td></tr><tr><td>Tablet</td><td>Oral</td><td>25 mg, 50 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>The antineoplasic agent decreases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole reduces metabolism and clearance of cyclophosphamide.</td></tr><tr><td><a href="/drugs/DB00552">Pentostatin</a></td><td>Increased toxicity of cyclophosphamide</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>Cyclophosphamide may increase the effect of succinylcholine.</td></tr><tr><td><a href="/drugs/DB04572">Thiotepa</a></td><td>Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Drink liberally- 2 to 3 liters/day.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>